Find Out More About Us

Who Are We

We are a research service provider specializing in oncology and immunotherapy, devoted to propelling targeted cancer therapy forward via the development of multispecific antibodies. With a team dedicated to precision and excellence, we are committed to pushing the boundaries of cancer therapeutics through innovative research and state-of-the-art platforms. By harnessing the latest advancements in immunotherapy, we strive to provide our customers with transformative therapy research services and together reshape the future of oncology.

Our Platform

Our cutting-edge ImmuBridge™ multispecific antibody platform is poised to redefine the landscape of cancer immunotherapy. This platform represents a paradigm shift in precision medicine, providing a foundation for developing multispecific antibodies that target both T cells and common tumor cell markers with unparalleled accuracy. By harnessing the power of T cell engagers (TCEs), we empower our customers’ cancer immunotherapy research and accelerate their path to commercialization.

By merging cutting-edge technology with a deep-rooted passion for healing, we strive to redefine the standards of immunotherapy and inspire hope in the fight against cancer.

Our Mission

Our core mission is to pioneer transformative solutions in oncology immunotherapy, leveraging innovation and compassion to empower patients in their fight against cancer.

Our Strategy

Through strategic investments in technology and talent, we seek to expand our reach and drive forward a portfolio of therapies that have the potential to transform the landscape of oncology.

Our Vision

We aspire to set new standards of excellence in oncology, shaping a future where cancer is not just treated but conquered through the power of the immune system and innovative therapies.

Our Commitment

We are unwavering in our dedication to advancing the field of tumor immunotherapy, improving patient outcomes, and making a positive impact on the lives of individuals affected by cancer.

Collaborate with Us to Leverage Our Robust Platform Support

We invite collaborators to join forces in harnessing the power of our ImmuBridge™ platform to drive forward the creation of cutting-edge therapies in tumor immunotherapy. By licensing our platform, you gain access to a wealth of scientific expertise, advanced technologies, and a proven track record of success in developing precision-targeted therapeutics for cancer. Embark on a transformative journey with us by collaborating to leverage the robust support of our platform for the development of multispecific antibody drugs.